Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MGC028

Antibody-drug conjugate · Cytotoxic, directed at ADAM9 · developed by MacroGenics

Phase 1 Most advanced trial
MGNX Developer
1 Registered trials

What is MGC028?

MGC028 is an antibody-drug conjugate in which a humanized anti-ADAM9 antibody is linked to the topoisomerase I inhibitor exatecan through a cleavable linker. The antibody binds ADAM9 on tumor cells, and after internalization the released exatecan inhibits DNA topoisomerase I, causing cell cycle arrest and apoptosis. It is studied in advanced solid tumors, non-small cell lung cancer adenocarcinoma, cholangiocarcinoma, pancreatic carcinoma and colorectal carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
ADAM9
Mechanism
Cytotoxic, directed at ADAM9
Pathways
DNA replication inhibition, cell cycle arrest, apoptosis, bystander effect on neighboring tumor cells
Therapy area
Oncology
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06723236 Phase 1 Advanced Solid Tumors Recruiting MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsCholangiocarcinomaColorectal CarcinomaNSCLC AdenocarcinomaPancreatic Carcinoma

Other drugs acting on ADAM9

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind MGC028

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.